New Premium Alert For Wednesday 9/13 Trading Session
Clinical-Stage Powerhouse Avalon GlobalCare Corp. (Ticker: ALBT)
This is Kevin Vander with "10XProTrader" delivering you your new premium alert for Wednesday 9/13 - trading session is Avalon GloboCare Corp. (NASDAQ: ALBT).
>>>> Interested In Potential Gains Like These Below <<<<
• (NAOV): Open at $2.10 8/30 – High $4.23 8/3/20 (101% Gains)
• (PRFX): Open at $2.10 8/30 – High $4.23 8/3/20 (101% Gains)
• (PRFX): Pre-Mkt at $5.37 7/3 – High $26.41 7/11 (391% Gains)
• (LIXT): Pre-Mkt at $5.26 7/17 – High $9.50 7/11 (80% Gains)
• (PWM): Pre-Mkt at $10.00 7/7 – High $31.88 7/11 (218% Gains)
• (DERM): Pre-Mkt at $1.50 7/3 – High $3.19 7/10 (112% Gains)
• (CRBU): Pre-Mkt at $4.13 7/6 – High $7.78 7/10 (88% Gains)
• (GRRR): Pre-Mkt at $3.25 7/7 – High $6.98 7/10 (114% Gains)
• (MOB): Pre-Mkt at $1.57 7/10 – High $3.33 (112% Gains)
Every single stock symbol you see above is an alert that I released to my 10X community. These are NOT fake alerts!
Premium Alert (ALBT) could quickly join the winning circle just like my real-time alerts you see posted above.
ALBT has been bouncing off its support level of $1.00/share twice during the last 30 days. Each swing up produced approx. 30% short-term gains.
It recently retracted back down to the $1.00+ level and I'm initiating coverage on this stock immediately.
Granted 30% is NOT a huge move, however...With its ultra small low float and the recent influx of news, I believe this stock could soon fly.
ALBT is a game-changing first mover with its FDA approved product.The breathalyzer is registered with the United States FDA as Class I medical device (US FDA registration # 3026284320).
Now Turn Your Complete Attention to Avalon GloboCare (NASDAQ: ALBT)
Our New Premium Nasdaq Biotech Breakout Alert for Wednesday!
Immediately Turn Your Attention to Avalon GloboCare (NASDAQ: ALBT)
Avalon GloboCare, Corp. (NASDAQ: ALBT), is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. The Company also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative research and development to automated bioproduction and accelerated clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. Founded in 2016; successfully uplisted to Nasdaq in December 2018; Headquarters in Freehold, New Jersey.
"Unleashing the Titans: Our Trio of Market-Dominating Tech Platforms!"
1. Delivering Precision Diagnostics and Laboratory Services
Avalon achieves and fosters seamless integration of unique verticals to bridge and accelerate innovative research, bio-process development, clinical programs and product commercialization.
2. Laboratory Services MSO
Lab Services MSO is focused on delivering high quality services related to toxicology and wellness testing and provides a broad portfolio of diagnostic tests including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, and sexually transmitted disease testing. The panels that Lab Services MSO tests for are thyroid panel, comprehensive metabolic panel, kidney profile, liver function tests, and other individual tests. Through Lab Services MSO, we use fast, accurate, and efficient equipment to provide practitioners with the tools to quickly determine if a patient is following their designated treatment plan.
We are exploring the commercialization and development of a versatile breathalyzer system. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The breathalyzer is registered with the United States FDA as Class I medical device (US FDA registration # 3026284320).
Revolutionary Key Clinical-Stage Milestones You Can Bank On!
Avalon GloboCare Corp. Has Achieved
It is very rare to see a low priced NASDAQ Biotech stock achieve as many clinical-stage milestones as this incredible little gem.
AVA-001: Avalon have successfully completed the first-in-human clinical trial of our AVA-001 anti-CD19 CAR-T cell therapy as a bridge to allogeneic bone marrow transplantation for patients with relapsed/refractory B-ALL at the Lu Daopei Hospital (registered clinical trial number NCT03952923) with excellent efficacy (90% complete remission rate) and minimal adverse side effects. We are currently expanding the indication and plan to recruit patients in the USA for AVA-001 to include both relapsed/refractory B-ALL and non-Hodgkin lymphoma patients.
AVA-011 and FLASH-CAR™: Avalon advanced its next generation immune cell therapy using mRNA-based, non-viral FLASH-CAR™ technology co-developed with our strategic partner Arbele Limited. The adaptable FLASH-CAR™ platform can be used to create personalized cell therapy from a patient's own cells, as well as off-the-shelf cell therapy from a universal donor. Our leading candidate, AVA-011, is currently at the process development stage to generate clinical-grade cell-therapy products for subsequent clinical studies.
AVA-Trap™: Avalon's AVA-Trap™ therapeutic program plans to enter animal model testing followed by expedited clinical studies with the goal of providing an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms. We initiated a sponsored research and co-development project with Massachusetts Institute of Technology (MIT) led by Professor Shuguang Zhang as Principal Investigator in May 2019. Using the unique QTY code protein design platform, six water-soluble variant cytokine receptors have been successfully designed and tested to show binding affinity to the respective cytokines. AVA-TrapTM can potentially generate novel therapeutic targets for cellular therapy, as well as in the field of precision diagnostics. We do not have a timeline for the next steps of this study.
"Avalon's Top Earning Drivers: The Revenue Powerhouses!"
#1.) Qualitative Drug Screening: We use fast, accurate, and efficient equipment to provide practitioners with the tools to quickly determine if a patient is following their designated treatment plan. In most instances, we are able to provide a practitioner with qualitative drug class results the same day the sample is received
#2.) Drug Testing by LCMS: We use top-of-the-line instrumentation to test for an extensive list of drugs to assist practitioners in ensuring patient treatment plan compliance. We are able to tell our practitioner clients what substances are in the patient's system and how much is present within 48 hours of sample receipt.
#3. Chemistry Wellness: We provide an extensive chemistry test menu that gives physicians the information to better treat their patients and maintain their overall wellness. The panels that we test for are thyroid panel, comprehensive metabolic panel, kidney profile, liver function tests, and other individual tests.
#4.) PCR COVID-19 Testing: Our lab offers highly complex and advanced PCR instrumentation to provide accurate, fast, and easy-to-understand results that tell physicians if their patients have been infected with the SARS-CoV-2 virus that causes COVID-19.
#5.) Urine Wellness Testing: Using Real-Time PCR, we are able to provide our physician clients with a comprehensive wellness test from a urine sample. The testing provides the physician with valuable information from an Anatomic Pathology Screen as well as a comprehensive STD/STI screen and a UTI test that includes antibiotic resistance.
#6.) (PGx) Testing: A PGx test uses real-time PCR to find genetic variants that affect how a person metabolizes various medications using DNA collected from a patient using a mouth swab. The testing can be used by clinicians to diagnose the cause of medication side effects, determine safe and appropriate dosing, reduce medication side effects, increase the effectiveness of medications, and avoid frustrating side effects.
"Avalon Uncovered: 7 Crucial Insights You Can't Afford to Miss!"
Avalon GloboCare Has an Extremely Low Float Producing Very High Volatile Swings In Price Movement
Avalon GloboCare Announces Notice of Publication for Key U.S. Patent Filed Jointly with the Massachusetts Institute of Technology (MIT)
Avalon GloboCare Subsidiary Launches New Laboratory Test For Tuberculosis
Avalon GloboCare Laboratory Services MSO Announces Expansion into Arizona
Avalon GloboCare Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth
Avalon GloboCare Reports Strong financial Results Laboratory Services MSO Revenue of $14.7Mln and Net Income of $6.3Mln in 2022
Avalon GloboCare Has Recently Bounced Off Its Support Level of $1.00/share Twice In The Last 30 Days for 30% Short=Term Gains
Could ALBT's FDA Approved Medical Device Make it a "Prime Acquisition Target" For Some of The Bigger Names in The Industry to Take Notice?
Avalon GloboCare Corp. (NASDAQ: ALBT) could become a potential prime acquisition target if it appeared on the radar of a larger pharmaceutical company.
Typically, when these the large-cap pharma and biotech companies find something of real value, they get noticed. And when that happens the big players either join them or buy them.
Conclusion: Avalon GloboCare Corp is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services.
The company is completely under-the-radar right now. The Biotech industry is a hot bed for take-over candidates. Could ALBT be a prime candidate?
I'm urging you and all of my 10X community to immediately put ALBT on your watchlist for Wednesday morning. You will receive another update.
Post a Comment
Post a Comment